2022 forecast: Talent war in life sciences, salary inflation in C-suite builds to 'negative feedback loop'

Biopharmas are not immune to the "Great Resignation" spurred by the pandemic, and drug developers will have to create new formulations to attract and retain talent, or at least improve current hiring practices, to stave off mass quitting in 2022.

The mass movement of talent through voluntary quitting and job shifting has hit every corner of the business world. Leaders across industries say they are struggling to find staff or hire candidates before competition poaches them, and meanwhile, C-suite paychecks are getting even thicker.